0001832511-26-000011
SEC filingP3 Health Partners' MD&A reveals a 3% revenue decline to $1.46B driven by strategic contract terminations, with a net loss of $323.1M and substantial doubt about its ability to continue as a going concern.
P3 Health Partners Inc. is a patient-centered and physician-led population health management company founded and led by physicians. The company operates in the $1,118 billion Medicare market, with a core focus on Medicare Advantage (MA), which covers approximately 34 million eligible lives. P3 manages the needs of its members through subscription-like per-member-per-month (PMPM) arrangements with health plans or payors. The company was formed through a business combination in December 2021 and is organized in an Up-C structure where P3 Health Partners Inc. is the sole manager of P3 Health Group, LLC, directly owning approximately 46% as of December 31, 2025. Substantially all assets and operations are conducted by P3 LLC and its subsidiaries.
The backbone of the P3 Care Model is the proprietary technology platform called P3 Technology/Health Hub, which integrates clinical and claims data from disparate sources to drive preventive care. The platform comprises three named products: Provider Portal, a physician-facing tool that provides risk-stratified patient lists, care opportunities, HEDIS gaps, and drug substitution opportunities; P3 Care Connect, a comprehensive management tool used by care management, utilization management, and concurrent review teams to deliver concierge care for high-risk populations; and Analytic Management Tools, a business intelligence platform that converts data into visualizations and real-time metrics, including an embedded Risk Adjustment engine for clinical risk stratification.
P3 typically leverages a community's existing healthcare infrastructure by contracting with local physicians using an affiliate model rather than building and staffing its own clinics or acquiring practices. This preserves the existing patient-physician relationship and provides a built-in patient panel on Day 1. The company augments these affiliate partnerships with employed Primary Care Physicians, P3-operated clinics, and wellness centers. P3 contracts with health plans to provide capitated care services for their MA members. Customer concentration is significant: contracts with four health plans collectively accounted for approximately 75% of total revenue for the year ended December 31, 2025, compared to four health plans accounting for approximately 59% in 2024. As of December 31, 2025, P3 had contracted with 2,400 primary care physicians, representing less than 1% of the approximately 544,000 PCPs in the U.S.
The healthcare industry is described as highly competitive and fragmented. P3's primary competition is the status quo fee-for-service environment. In the population health management space, named competitors include Aledade, Astrana Health, and agilon health, along with numerous local provider networks, hospitals, and health systems. Large, well-financed payors have also developed their own managed care services tools. Principal competitive factors include the nature and caliber of physician relationships, patient healthcare quality and outcomes, strength of payor relationships, quality of the physician experience, local geography leadership position, and strength of the underlying economic model.
P3 pursues a disciplined growth strategy with five stated pillars. First, the company aims to capture additional membership through current relationships as Medicare-eligible patients and MA penetration rates increase. Second, it seeks expansion in current markets (Arizona, California, Nevada, and Oregon) by offering a compelling value proposition for physicians shifting to value-based care while remaining independent. Third, P3 employs a land-and-expand strategy to enter adjacent markets by leveraging regional infrastructure and payor relationships. Fourth, the company evaluates a pipeline of new market opportunities through new payor contracts, network partnerships, or joint ventures. Fifth, P3 intends to execute on accretive acquisitions to acquire additional lives across both physicians and payors. The company also conducts periodic strategic reviews of provider and payor contracts and may exit underperforming relationships to rationalize network costs.
As of December 31, 2025, P3 had approximately 320 full-time employees, none of whom are represented by a labor union or party to a collective bargaining agreement. The company considers its employee relationships to be good. P3's human capital objectives include sourcing, recruiting, developing, retaining, rewarding, recognizing, and integrating employees. The company's core values are organized around People, Passion, and Purpose, with sub-values including Collaboration, Service, Accountability, Empowerment, Innovation, and Adaptability. The company also reported an annual physician retention rate of over 88% for 2025, reflecting the strength of its affiliate physician partnerships.
For the year ended December 31, 2025, P3 Health Partners reported a 3% decline in total operating revenue to $1.46 billion, down from $1.50 billion in the prior year. This was primarily driven by a 4% decrease in capitated revenue, the company's core business, which fell to $1.43 billion. The decline was attributed to a 7% reduction in the average number of at-risk members, from 126,000 in 2024 to 116,100 in 2025. Management explicitly linked this contraction to the strategic termination of underperforming payor contracts and affiliate providers, a deliberate effort to improve the quality of the network. This was partially offset by a 79% surge in other revenue to $30.1 million, driven by incentive-sharing arrangements related to Part D programs.
Despite the revenue contraction, the company's operating loss improved by 16% to $270.3 million, compared to a $320.7 million loss in 2024. This improvement was largely due to a $34.9 million reduction in premium deficiency reserve (PDR) expense, which fell to $18.7 million from $53.7 million. However, the core profitability metric, Medical Margin, deteriorated sharply, falling 72% to $23.5 million from $85.5 million, indicating that the cost of medical claims consumed nearly all capitated revenue. The net loss widened by 4% to $323.1 million, heavily impacted by a $32.9 million increase in net interest expense to $55.0 million, reflecting a growing debt burden from multiple new financing arrangements. The operating margin improved by 200 basis points to -19%, though this was influenced by the volatile PDR and impairment charges.
The company operates a single reportable segment focused on its population health management platform. The core capitated revenue stream, representing 98% of total revenue, is under significant pressure. The strategic pruning of the network, while causing a near-term revenue headwind, is intended to create a more sustainable base. The sharp decline in Medical Margin to just $23.5 million underscores the challenge of managing medical costs for the remaining 115,100 at-risk members. The company's gross profit, which includes other medical expenses like physician surplus sharing, was a loss of $60.2 million, slightly worse than the $58.9 million loss in the prior year.
On the cost side, the company demonstrated operating leverage in its platform support costs, which decreased to 5.9% of total revenue from 6.1%. Corporate, general and administrative expenses fell by 6% to $106.3 million, driven by an 11% reduction in headcount and lower non-income based taxes. This was partially offset by a $6.2 million gain in the prior year from a contingent consideration settlement that did not recur. The company's affiliate physician network contracted significantly, ending the year with 2,400 PCPs compared to 3,100 at the end of 2024, consistent with the strategic contract terminations.
The MD&A presents a critical forward view centered on liquidity and viability. Management has concluded that there is substantial doubt about the company's ability to continue as a going concern within one year. With only $25.0 million in unrestricted cash and an accumulated deficit of $651.1 million, the company believes it will require additional funding in 2026, even after receiving $18 million from a related-party financing in early 2026. The company's strategy involves continuing to explore raising capital through debt, equity, or asset sales, but acknowledges there is no assurance these will be available on satisfactory terms. The independent auditor has also expressed substantial doubt about the going concern assumption. The company's future depends on its ability to secure financing, manage medical costs effectively, and potentially curtail planned activities if capital is not secured.
As of December 31, 2025, the Company's financial position is severely strained. Cash and cash equivalents stand at $25.0 million, down from $38.8 million the prior year. The Company reports a working capital deficit of $412.2 million and a total stockholders' deficit of $155.2 million. The auditor's report and Note 2 explicitly state that these conditions, along with recurring operating losses, raise substantial doubt about the Company's ability to continue as a going concern. The consolidated balance sheet includes $8.2 million in assets from consolidated VIEs that can only be used to settle VIE obligations.
The Notes do not detail traditional purchase commitments. The primary contractual obligations are debt-related. Gross long-term debt totals $336.7 million, with maturities of $45.1 million in 2026, $110.7 million in 2027, and $181.0 million in 2028. The Company has significant operating lease liabilities totaling $13.9 million, with $3.9 million due within one year. A key liability is the Premium Deficiency Reserve (PDR), which increased to $86.1 million from $67.4 million, reflecting management's estimate that future health care costs will exceed premiums on existing contracts. Claims payable also increased to $287.8 million.
The Company did not repurchase shares or pay dividends. Capital allocation is dominated by debt financing. During 2025, the Company drew $73.0 million in new long-term debt, net of discount, primarily through new VGS promissory notes (VGS 4 and VGS 5) with interest rates of 19.5%. These notes also include back-end fees of up to 9.0%. Proceeds from liability-classified warrants and equity were $0 in 2025, compared to $40.5 million in 2024. The Company repaid $1.1 million in debt. Capital expenditures were minimal at $0.1 million. The Company also issued equity-classified warrants to lenders, recording $26.7 million to additional paid-in capital.
Note 19 confirms the Company operates as a single reportable segment. It provides population health management services on an at-risk basis to Medicare Advantage plans. As of December 31, 2025, the Company had at-risk contracts with 24 health plans across four states, down from 23 plans across five states in 2024. Four health plan customers accounted for 75% of total revenue in 2025, indicating significant customer concentration. Capitated revenue made up 97.9% of total operating revenue.
The most critical risk disclosed is management's identification of substantial doubt about the company's ability to continue as a going concern within one year. As of December 31, 2025, P3 Health Partners had only $25.0 million in unrestricted cash against $336.7 million in outstanding indebtedness and $287.8 million in unpaid claims. The company expects continued operating losses and negative cash flows, requiring additional funding in 2026. A related-party financing transaction in early 2026 provided $18.0 million, but this is insufficient to fund operations for the next 12 months without additional capital. The company's history of significant net losses ($323.1 million in 2025, accumulated deficit of $651.1 million) compounds this risk. Furthermore, non-compliance with debt covenants related to the 'going concern' audit opinion required a waiver from lenders, with no assurance of future waivers.
Regulatory risks are prominent. Medcore HP, a California subsidiary, failed to meet the DMHC's positive tangible net equity requirement, necessitating a corrective action plan submitted in March 2026. Non-compliance could lead to sanctions or termination of business in California. The company also disclosed receiving a civil investigative demand (CID) from the DOJ in June 2024 concerning arrangements with insurance agents and brokers, potentially implicating the False Claims Act and anti-kickback statute. The evolving regulatory landscape for AI technologies and value-based reimbursement models adds further uncertainty.
The company's near-total dependence on Medicare Advantage revenue creates significant exposure to CMS policy changes. The Advance Notice for calendar year 2027 estimates an average MA reimbursement increase of only 0.09%, with proposed changes to risk adjustment methodology and star ratings that could materially reduce revenue. Payor concentration is high, with four health plans accounting for approximately 75% of 2025 revenue. The transition from the ACO REACH model to the ACO LEAD model introduces additional operational and financial uncertainty.
Intangible assets represent 75% of total assets ($492.4 million), creating ongoing impairment risk if operating performance declines. The company faces intense competition from entities like Aledade, Astrana Health, and agilon health, as well as challenges in recruiting and retaining physicians amid labor shortages. Nasdaq listing compliance is at risk following a deficiency letter for not meeting the minimum $2.5 million stockholders' equity requirement, with an extension granted until May 20, 2026.
P3 Health Partners Inc.'s cash flow statement reveals significant deterioration in operating cash flow, which swung from -$55.9 million in 2024 to -$138.5 million in 2025. This negative trend far outpaces the net loss, indicating poor cash conversion and potential working capital headwinds. The company's core operations are consuming substantial cash, a critical concern given the going concern uncertainty noted by auditors.
Capital expenditures are minimal at $0.3 million, reflecting an asset-light model with low capex intensity. Consequently, free cash flow is not materially different from operating cash flow and remains deeply negative. The company did not engage in any share repurchases or dividend payments, preserving what little liquidity it has.
Financing cash flows were flat at $0.0 million, suggesting no new external capital was raised during the period to offset the operational cash burn. The absence of financing inflows, combined with the escalating operating cash outflows, underscores the severe liquidity strain and the substantial doubt regarding the company's ability to continue as a going concern without additional capital or a dramatic operational turnaround.